Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesnatilimab in Alopecia Areata
NCT04740970Phase 2Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of NNC0142-0002 in alopecia areata, sponsored by Janssen Pharmaceutical. Planned start Mar 2021; status: withdrawn.
02
Drugs
NNC0142-0002
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT04740970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04740970.